1. Home
  2. EBS vs NPCE Comparison

EBS vs NPCE Comparison

Compare EBS & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EBS
  • NPCE
  • Stock Information
  • Founded
  • EBS 1998
  • NPCE 1997
  • Country
  • EBS United States
  • NPCE United States
  • Employees
  • EBS N/A
  • NPCE N/A
  • Industry
  • EBS Biotechnology: Pharmaceutical Preparations
  • NPCE Medical Specialities
  • Sector
  • EBS Health Care
  • NPCE Health Care
  • Exchange
  • EBS Nasdaq
  • NPCE Nasdaq
  • Market Cap
  • EBS 423.6M
  • NPCE 342.7M
  • IPO Year
  • EBS 2006
  • NPCE 2021
  • Fundamental
  • Price
  • EBS $9.11
  • NPCE $10.82
  • Analyst Decision
  • EBS Strong Buy
  • NPCE Strong Buy
  • Analyst Count
  • EBS 2
  • NPCE 6
  • Target Price
  • EBS $13.50
  • NPCE $16.67
  • AVG Volume (30 Days)
  • EBS 969.4K
  • NPCE 149.8K
  • Earning Date
  • EBS 10-29-2025
  • NPCE 11-11-2025
  • Dividend Yield
  • EBS N/A
  • NPCE N/A
  • EPS Growth
  • EBS N/A
  • NPCE N/A
  • EPS
  • EBS 2.53
  • NPCE N/A
  • Revenue
  • EBS $851,600,000.00
  • NPCE $88,570,000.00
  • Revenue This Year
  • EBS N/A
  • NPCE $22.13
  • Revenue Next Year
  • EBS $19.24
  • NPCE $6.07
  • P/E Ratio
  • EBS $3.63
  • NPCE N/A
  • Revenue Growth
  • EBS N/A
  • NPCE 23.32
  • 52 Week Low
  • EBS $4.02
  • NPCE $5.45
  • 52 Week High
  • EBS $12.73
  • NPCE $18.98
  • Technical
  • Relative Strength Index (RSI)
  • EBS 54.66
  • NPCE 57.95
  • Support Level
  • EBS $9.07
  • NPCE $10.25
  • Resistance Level
  • EBS $10.10
  • NPCE $11.25
  • Average True Range (ATR)
  • EBS 0.49
  • NPCE 0.50
  • MACD
  • EBS 0.01
  • NPCE -0.02
  • Stochastic Oscillator
  • EBS 53.00
  • NPCE 65.44

About EBS Emergent Biosolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

About NPCE Neuropace Inc.

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Share on Social Networks: